EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 3.0

A Prospective, Single-Cohort, Open, Multi-center, Observational Study of Sublingual Fentanyl for Breakthrough Cancer Pain: Effectiveness, Safety, and Tolerability in Korean Cancer Patients

Youn Seon Choi, Su-Jin Koh, Woo Kyun Bae, Se Hyung Kim, Seong Hoon Shin, So Yeon Oh, Sang Byung Bae, Yaewon Yang, Eun-Kee Song, Yoon Young Cho, Pyung Bok Lee, Ho-Suk Oh und 2 weitere

Cancer Research and Treatment · 2025

DOI: 10.4143/crt.2024.557 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Youn Seon Choi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine, Korea University Guro Hospital, Seoul, Korea. Hauptthemen laut MEDLINE: Fentanyl, Cancer Pain, Breakthrough Pain, Analgesics, Opioid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: A.Menarini Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Fentanyl, a highly lipophilic opioid, was developed as a sublingual fentanyl tablet (SFT) for the management of breakthrough cancer pain (BTcP), and its efficacy and safety were confirmed in a randomized, controlled study. We investigated the effectiveness and safety of SFT administered to alleviate BTcP in a real-world setting.Materials and Methods In this prospective, open, single-cohort study, conducted in 13 referral hospitals in South Korea, opioid-tolerant cancer patients receiving around-the-clock opioids for persistent cancer pain were enrolled if the individual had BTcP ≥ 1 episode/day during the preceding week. The primary outcome was the SFT titration success rate.

Results

Among 113 patients evaluated for effectiveness, 103 patients (91.2%) had a successful titration of SFT, with an effective dose range between 100 μg and 400 μg. The most frequent dose was 100 μg, administered to 65.0%, 72.1%, and 81.8% of the patients at week 1, 4, and 12, respectively. The proportion of patients achieving the personalized pain goal assessed in the first week was 75.2%. The mean change in pain intensity measured with a numeric rating scale at 30 and 60 minutes after taking SFT was –2.57 and –3.62, respectively (p < 0.001 for both). The incidence rate of adverse events related to SFT among 133 patients included for safety evaluation was 9.0% (12/133), which included vomiting (3.0%), nausea (2.3%), and headache (1.5%).

Conclusion

In a real-world setting, SFT provides rapid and effective analgesia in BTcP, even at the lowest dose (100 μg), and the safety profile was acceptable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FentanylCancer PainBreakthrough PainAnalgesics, OpioidNeoplasmsHumansFemaleMaleMiddle AgedAdministration, SublingualAgedProspective StudiesRepublic of KoreaAdultTreatment OutcomePain Measurement

Stichwörter der Autor:innen

AdministrationAnalgesicsBreakthrough painCancer painFentanylOpioidPain measurement

Substanzen

FentanylAnalgesics, Opioid

Autor:innen und Institutionen

  • Department of Family Medicine, Korea University Guro Hospital, Seoul, Korea.
  • Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
  • Department of Internal Medicine, Chonnam National University Medical School, Hwasun, Korea.
  • Division of Hematology and Oncology, Soonchunhyang University Hospital Bucheon, Bucheon, Korea.
  • Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea.
  • Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University Medical School, Yangsan, Korea.

Förderung

  • A.Menarini Korea

Zitieren

APA

Choi, Y. S., Koh, S. J., Bae, W. K., Kim, S. H., Shin, S. H., Oh, S. Y., Bae, S. B., Yang, Y., Song, E. K., Cho, Y. Y., Lee, P. B., Oh, H. S., Lee, M., & Ahn, J. S. (2025). A Prospective, Single-Cohort, Open, Multi-center, Observational Study of Sublingual Fentanyl for Breakthrough Cancer Pain: Effectiveness, Safety, and Tolerability in Korean Cancer Patients. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.557

Vancouver

Choi YS, Koh SJ, Bae WK, Kim SH, Shin SH, Oh SY, et al. A Prospective, Single-Cohort, Open, Multi-center, Observational Study of Sublingual Fentanyl for Breakthrough Cancer Pain: Effectiveness, Safety, and Tolerability in Korean Cancer Patients. Cancer Research and Treatment. 2025. doi:10.4143/crt.2024.557

BibTeX
@article{Choi2025,
  author = {Choi, Youn Seon and Koh, Su-Jin and Bae, Woo Kyun and Kim, Se Hyung and Shin, Seong Hoon and Oh, So Yeon and Bae, Sang Byung and Yang, Yaewon and Song, Eun-Kee and Cho, Yoon Young and Lee, Pyung Bok and Oh, Ho-Suk and Lee, MinYoung and Ahn, Jin Seok},
  title = {A Prospective, Single-Cohort, Open, Multi-center, Observational Study of Sublingual Fentanyl for Breakthrough Cancer Pain: Effectiveness, Safety, and Tolerability in Korean Cancer Patients},
  journal = {Cancer Research and Treatment},
  year = {2025},
  doi = {10.4143/crt.2024.557}
}
Kostenlos starten →